Prognostic Implications of p27 and Cyclin E Protein Contents in Malignant Lymphomas

References

• Sherr C. J. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Elledge S. Cell cycle checkpoints: Preventing an identity crisis. Science 1995; 274: 1664–1672
   Web of Science ®Google Scholar
• Guan K. L., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Matera A. G., Xiong Y. Growth suppression by p18, a p16INK4/MTS1-and p141NK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Development 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Harper J. W., Elledge S. J., Keyomarsi K., Dynlacht B., Tsai L. H., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., Fox M. P., Wei N. Inhibition of cyclin-dependent kinases by p21. Molecular Biology of the Cell 1995; 6: 387–400
   PubMed Web of Science ®Google Scholar
• Bartkova J., Lukas J., Bartek J. Aberrations of the G1-and G1/S-regulating genes in human cancer. Progress in Cell Cycle Research 1997; 3: 211–220
   PubMedGoogle Scholar
• Dreyling M. H., Bullinger L., Ott G., Stilgenbauer S., Müller-Hermenlink H. K., Bentz M., Hiddemann W., Dormer H. Alterations of the cyclin D1/p16-pRb pathway in mantle cell lymphoma. Cancer Research 1997; 57: 4608–4614
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K. C., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Müller-Hermenlink H.-K., Piled S. A., Piris M. A., Ralfkiaer E., Warnke R. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Olopade O. I., Bohlander S. K., Pomykala H., Maltepe E., Van Melle E., Le Beau M. M., Diaz M. O. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 1992; 14: 437–443
   PubMed Web of Science ®Google Scholar
• Ogawa S., Hangaishi A., Miyawaki S., Hirosawa S., Miura Y., Takeyama K., Kamada N., Ohtake S., Uike N., Shimazaki C. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86: 1548–1556
   PubMed Web of Science ®Google Scholar
• Villuendas R., Sanchez-Beato M., Martinez J. C., Saez A. I., Martinez-Delgado B., Garcia J. K., Mateo M. S., Sanchez-Verde L., Benitez J., Martinez P., Piris M. A. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. American Journal of Pathology 1998; 153: 887–897
   PubMed Web of Science ®Google Scholar
• Hangaishi A., Ogawa S., Imamura N., Miyawaki S., Miura Y., Uike N., Shimazaki C., Emi N., Takeyama K., Hirosawa S., Kamada N., Kobayashi Y., Takemoto Y., Kitani T., Toyama K., Ohtake S., Yazaki Y., Ueda R., Hirai H. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTSl/pl6INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87: 4949–4958
   PubMed Web of Science ®Google Scholar
• Geradts J., Andriko J. W., Abbondanzo S. L. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. American Journal of Clinical Pathology 1998; 109: 669–674
   PubMed Web of Science ®Google Scholar
• Tao W., Levine A. J. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Procedings of National Academy of Science in U S A 1999; 96: 6937–6941
   PubMed Web of Science ®Google Scholar
• Gardie B., Cayuela J. M., Martini S., Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91: 1016–1020
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Chikatsu N., Takahashi S., Fujita A., Uchimaru K., Asano S., Fujita T., Motokura T. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 1999; 13: 1760–1769
   PubMed Web of Science ®Google Scholar
• Shiohara M., Spirin K., Said J. W., Gombart A. F., Nakamaki T., Takeuchi S., Hatta Y., Morosetti R., Tasaka T., Seriu T., Bartram C., Miller C. W., Tomonaga M., Koeffler H. P. Alterations of the cyclin-dependent kinase inhibitor p 19 (INK4D) is rare in hematopoietic malignancies. Leukemia 1996; 10: 1897–1900
   PubMed Web of Science ®Google Scholar
• Ohtsubo M., Theodoras A. M., Schumacher J., Roberts J. M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molecular and Cellular Biology 1995; 15: 2612–2624
   PubMed Web of Science ®Google Scholar
• Nielsen N. H., Emdin S. O., Cajander J., Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997; 14: 295–304
   PubMed Web of Science ®Google Scholar
• Marone M., Scambia G., Giannitelli C., Ferrandina G., Masciullo V., Bellacosa A., Benedetti-Panici P., Mancuso S. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. International Journal of Cancer 1998; 75: 34–39
   PubMed Web of Science ®Google Scholar
• Bortner D. M., Rosenberg M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Molecular Biology of the Cell 1997; 17: 453–459
   Web of Science ®Google Scholar
• Porter P., Malone K., Heagerty P., Alexander G., Gatti L., Firpo E., Daling J., Roberts J. Expression of cell-cycle regulators p27kipf and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 1997; 3: 222–225
   PubMed Web of Science ®Google Scholar
• Nielsen N. H., Arnelöv C., Emdin S. O., Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. British Journal of Cancer 1996; 74: 874–880
   PubMed Web of Science ®Google Scholar
• Jang S. J., Park Y. W., Park M. H., Lee J. D., Lee Y. Y., Jung T. J., Kim I. S., Choi I. Y., Ki M., Choi B. Y., Ahn M. J. Expression of cell-cycle regulators, cyclin E and p21WAFl/CIP1, potential prognostic markers for gastric cancer. European Journal of Surgical Oncology 1999; 25: 157–163
   PubMed Web of Science ®Google Scholar
• Kim S. H., Lewis J. J., Brennan M. F., Woodruff J. M., Dudas M., Cordon-Cardo C. Overexpression of cyclin Dl is associated with poor prognosis in extremity soft-tissue sarcomas. Clinical Cancer Research 1998; 4: 2377–2382
   PubMed Web of Science ®Google Scholar
• Scuderi R., Palucka K. A., Pokrovskaja K., Björkholm M., Wiman K. G., Pisa P. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 1996; 87: 3360–3367
   PubMed Web of Science ®Google Scholar
• Wolowiec D., Benchaib M., Pernas P., Deviller P., Soucher C., Rimokh R., Felman P., Bryon P. A., Ffrench M. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue. Leukemia 1995; 9: 1382–1388
   PubMed Web of Science ®Google Scholar
• Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92: 770–777
   PubMed Web of Science ®Google Scholar
• Alessandrini A., Chiaur D. S., Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997; 11: 342–345
   PubMedGoogle Scholar
• Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massague J. Cioning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59–66
   PubMed Web of Science ®Google Scholar
• Kato J. Y., Matsuoka M., Polyak K., Massague J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496
   PubMed Web of Science ®Google Scholar
• Fornaro M., Tallini G., Zheng D. Q., Flanagan W. M., Manzotti M., Languino L. R. p27(kipl) acts as a downstream effector of and is coexpressed with the beta 1C integrin in prostatic adenocarcinoma. Journal of Clinical Investigation 1999; 103: 321–329
   PubMed Web of Science ®Google Scholar
• Rogatsky I., Trowbridge J. M., Garabedian M. J. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Molecular Biology of the Cell 1997; 17: 3181–3193
   Web of Science ®Google Scholar
• Scott D. W., Donjerkovic D., Maddox B., Ezhevsky S., Grdina T. Role of c-myc and p27 in anti-IgM induced B-lymphoma apoptosis. Current Topics in Microbiology and Immunology 1997; 224: 103–112
   PubMed Web of Science ®Google Scholar
• Katayose Y., Kim M., Rakkar A. N., Li Z., Cowan K. H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Research 1997; 57: 5441–5445
   PubMed Web of Science ®Google Scholar
• Ezhevsky S.A., Toyoshima H., Hunter T., Scott D. W. Role of cyclin A and p27 in anti-IgM induced Gl growth arrest of murine B-cell lymphomas. Molecular Biology of the Cell 1996; 7: 553–564
   PubMed Web of Science ®Google Scholar
• Sánchez-Beato M., Saez A. I., Martinez-Montero J. C., Sol-Mateo M., Sanchez-Verde L., Villuendas R., Troncone G., Piris M. A. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. American Journal of Patholology 1997; 151: 151–160
   PubMed Web of Science ®Google Scholar
• Kawana H., Tamaru J., Tanaka T., Hirai A., Saito Y., Kitagawa M., Mikata A., Harigaya K., Kuriyama T. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. American Journal of Patholology 1998; 153: 505–513
   PubMed Web of Science ®Google Scholar
• Palmqvist R., Stenling R., Öberg Å., Landberg G. Prognostic significance of p27(Kipl) expression in colorectal cancer: a clinico-pathological characterization. Journal of Pathology 1999; 188: 18–23
   PubMed Web of Science ®Google Scholar
• Møller M. B., Skjødt K., Mortensen L. S., Pedersen N. T. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. British Journal of Haematology 1999; 105: 730–736
   PubMed Web of Science ®Google Scholar
• Sáez A., Sanchez E., Sanchez-Beato M., Cruz M. A., Chacon I., Munoz E., Camacho F. I., Martinez-Montero J. C., Mollejo M., Garcia J. F., Piris M. A. p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome. British Journal of Cancer 1999; 80: 1427–1434
   PubMed Web of Science ®Google Scholar
• Loden M., Nielsen N. H., Roos G., Emdin S. O., Landberg G. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 1999; 18: 2557–2566
   PubMed Web of Science ®Google Scholar
• Lloyd R. V., Erickson L. A., Jin L., Kulig E., Qian X., Cheville J. C., Scheithauer B. W. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. American Journal of Pathology 1999; 154: 313–323
   PubMed Web of Science ®Google Scholar
• Tsvetkov L. M., Yeh K. H., Lee S. J., Sun H., Zhang H. p27(Kipl) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Current Biology 1999; 9: 661–664
   PubMed Web of Science ®Google Scholar
• Cote R. J., Shi Y., Groshen S., Feng A. C., Cordon-Cardo C., Skinner D., Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. Journal of National Cancer Institute 1998; 90: 916–920
   PubMed Web of Science ®Google Scholar
• Cheville J. C., Lloyd R. V., Sebo T. J., Cheng L., Erickson L., Bostwick D. G., Lohse C. M., Wollan P. Expression of p27Kip1 in prostatic adenocarcinoma. Modern Pathology 1998; 11: 324–328
   PubMed Web of Science ®Google Scholar
• Yang R. M., Naitoh J., Murphy M., Wang H. J., Phillipson J., deKernion J. B., Loda M., Reiter R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. Journal of Urology 1998; 159: 941–945
   PubMed Web of Science ®Google Scholar
• Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a.b) invasive breast carcinomas. Cancer Research 1997; 57: 1259–1263
   PubMed Web of Science ®Google Scholar
• Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Research 1997; 57: 3381–3385
   PubMed Web of Science ®Google Scholar
• Jang S. J., Ahn M. J., Paik S. S., Kong G., Keum J. S., Park Y. W., Lee J. D. Expression of cyclin dependent kinase inhibitor p21WAF1 alone and in combination with p27KIP1 shows prognostic value in gastric carcinoma. Journal of Korean Medical Science 1998; 13: 369–376
   PubMedGoogle Scholar
• Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Japanese Journal of Cancer Research 1997; 88: 625–629
   PubMedGoogle Scholar
• Iida H., Towatari M., Tanimoto M., Morishita Y., Kodera Y., Saito H. Overexpression of cyclin E in acute myelogenous leukemia. Blood 1997; 90: 3707–3713
   PubMed Web of Science ®Google Scholar
• Hayette S., Thomas X., Bertrand Y., Tigaud I., Callanan M., Thiebaut A., Charrin C., Archimbaud E., Magaud J. P., Rimokh R. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997; 11: 1696–1699
   PubMed Web of Science ®Google Scholar
• Morosetti R., Kawamata N., Gombart A. F., Miller C. W., Hatta Y., Hirama T., Said J. W., Tomonaga M., Koeffler H. P. Alterations of the p27Kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86: 1924–1930
   PubMed Web of Science ®Google Scholar
• Vrhovac R., Delmer A., Tang R., Marie J. P., Zittoun R., Ajchenbaum-Cymbaiista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998; 91: 4694–4700
   PubMed Web of Science ®Google Scholar
• Anayama T., Furihata M., Ishikawa T., Ohtsuki Y., Ogoshi S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. International Journal of Cancer 1998; 79: 439–443
   PubMed Web of Science ®Google Scholar
• St Croix B., Florenes V. A., Rak J. W., Flanagan M., Bhattacharya N., Slingerland J. M., Kerbel R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nature Medicine 1996; 11: 1204–1210
   Google Scholar